Antibody drug conjugates in clinics

This presentation explores Antibody Drug Conjugates (ADCs), highlighting their role in revolutionising cancer therapy through targeted approaches. Starting with the definition and benefits of ADCs, it delves into key components like antibodies, linkers, and cytotoxic payloads, explaining their mechanism of tumour-specific action. It examines FDA-approved ADCs, discusses ongoing clinical trials, and considers future innovations, addressing challenges such as drug resistance and production...